Featured Research

from universities, journals, and other organizations

Going From Ulcers To Cancer

Date:
August 24, 2008
Source:
American Society for Biochemistry and Molecular Biology
Summary:
Researchers have uncovered a big clue as to why some of the bacteria that cause stomach ulcers pose a greater risk for serious problems like stomach cancer than others; it turns out these bacteria can exploit the surrounding stomach cells to protect them from the immune system.

Researchers have uncovered a big clue as to why some of the bacteria that cause stomach ulcers pose a greater risk for serious problems like stomach cancer than others; it turns out these bacteria can exploit the surrounding stomach cells to protect them from the immune system.

Helicobacter pylori is a bacterial strain that can infect the human stomach and induce inflammation, ulcers, and potentially even stomach cancer. However, only a small fraction of H. pylori infections ultimately lead to cancer, leading researchers to figure out what biological events will trigger this path.

One type of H. pylori strain that seems to increase disease risk is the cag+ strain, which contains a set of proteins that allows it to inject bacterial proteins into cells following attachment to the stomach lining; this interaction between bacteria and gastric cells may be a key contributor to chronic damage.

Richard Peek and colleagues investigated a cag+ strain in mouse models of H. pylori infection and found that a protein called CagE could induce gastric cells to turn on a receptor called Decay-accelerating factor (DAF); DAF acts to remove nearby immune proteins that can kill cells to prevent unwanted immune damage.

In essence, the bacteria use the DAF receptor on the host cell they're attached to like a bodyguard to protect them from the immune system. Peek and colleagues also note that by continually inducing DAF expression, H. pylori creates an environment of persistent inflammation that can reduce the threshold required for more serious diseases to develop.


Story Source:

The above story is based on materials provided by American Society for Biochemistry and Molecular Biology. Note: Materials may be edited for content and length.


Journal Reference:

  1. O'Brien et al. Regulation of the Helicobacter pylori Cellular Receptor Decay-accelerating Factor. Journal of Biological Chemistry, 2008; 283 (35): 23922 DOI: 10.1074/jbc.M801144200

Cite This Page:

American Society for Biochemistry and Molecular Biology. "Going From Ulcers To Cancer." ScienceDaily. ScienceDaily, 24 August 2008. <www.sciencedaily.com/releases/2008/08/080822120144.htm>.
American Society for Biochemistry and Molecular Biology. (2008, August 24). Going From Ulcers To Cancer. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/08/080822120144.htm
American Society for Biochemistry and Molecular Biology. "Going From Ulcers To Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/08/080822120144.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins